Loading organizations...
§ Private Profile · Lexington, MA, USA
Clinical-stage biotech developing oral gut-targeted antibody therapeutics for inflammatory and gastrointestinal diseases.
Founded in November 2005 by Barbara Fox and David Poorvin, Avaxia Biologics was a Lexington, Massachusetts clinical stage biopharmaceutical company developing orally delivered, gut targeted antibody therapeutics. The proprietary platform focused on treating gastrointestinal conditions like inflammatory bowel disease and oral mucositis, providing localized efficacy without the systemic side effects of injected antibodies. Before suspending operations in late 2015, the biotechnology startup successfully advanced its lead drug candidate, AVX-470, through positive Phase 1b clinical trials for ulcerative colitis. The enterprise raised over twenty-two million dollars in total funding, including an eleven point four million dollar Series B financing round to support ongoing research and development efforts. This financial backing featured a one and a half million dollar grant from the Crohn's and Colitis Foundation, alongside strategic investments from Cherrystone Angel Group, Golden Seeds, and Mass Medical Angels.
Avaxia Biologics has raised $15.5M across 2 funding rounds.
Avaxia Biologics has raised $15.5M in total across 2 funding rounds.
Avaxia Biologics has raised $15.5M across 2 funding rounds. Most recently, it raised $11.4M Series B in June 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 7, 2013 | $11.4M Series B | Robert Manning, Nada Jain | AbbVie Ventures, Ariel Southeast Angel Partners, Beacon Angels, Beta Fund, Boston Harbor Angels, Granite State Angels, Keiretsu Forum, Launchpad Venture Group, Maine Angels, Mass Medical Angels, North Country Angels, Tech Coast Angels | Announced |
| Feb 14, 2012 | $4.1M Series A | Robert Manning | Beacon Angels, Boston Harbor Angels, Henry KAY, Mass Medical Angels, North Country Angels | Announced |
Avaxia Biologics has raised $15.5M in total across 2 funding rounds.
Avaxia Biologics's investors include Robert Manning, Nada Jain, AbbVie Ventures, Ariel Southeast Angel Partners, Beacon Angels, Beta Fund, Boston Harbor Angels, Granite State Angels, Keiretsu Forum, Launchpad Venture Group, Maine Angels, Mass Medical Angels.